MX2016003394A - Formulaciones para antagonistas del receptor del cgrp. - Google Patents

Formulaciones para antagonistas del receptor del cgrp.

Info

Publication number
MX2016003394A
MX2016003394A MX2016003394A MX2016003394A MX2016003394A MX 2016003394 A MX2016003394 A MX 2016003394A MX 2016003394 A MX2016003394 A MX 2016003394A MX 2016003394 A MX2016003394 A MX 2016003394A MX 2016003394 A MX2016003394 A MX 2016003394A
Authority
MX
Mexico
Prior art keywords
cgrp receptor
receptor antagonists
formulations
pharmaceutical compositions
liquid pharmaceutical
Prior art date
Application number
MX2016003394A
Other languages
English (en)
Inventor
Wei Xu
Majid Mahjour
Sutthilug Sotthivirat
R Allain Leonardo
G Maus Russell
NOFSINGER Rebecca
LUPTON Lisa
Flanagan Francis
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016003394A publication Critical patent/MX2016003394A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas líquidas que contienen antagonistas del receptor de CGRP; las composiciones farmacéuticas líquidas del antagonista del receptor del CGRP de la presente invención son composiciones farmacéuticas líquidas de bajo volumen y libres de alcohol que se pueden tomar sin agua para el tratamiento de cefalea por migraña.
MX2016003394A 2013-09-16 2014-09-11 Formulaciones para antagonistas del receptor del cgrp. MX2016003394A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878183P 2013-09-16 2013-09-16
PCT/US2014/055132 WO2015038736A2 (en) 2013-09-16 2014-09-11 Formulations for cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
MX2016003394A true MX2016003394A (es) 2016-10-28

Family

ID=52666511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003394A MX2016003394A (es) 2013-09-16 2014-09-11 Formulaciones para antagonistas del receptor del cgrp.

Country Status (13)

Country Link
US (3) US20160220552A1 (es)
EP (2) EP3915561A1 (es)
JP (1) JP6612234B2 (es)
KR (3) KR20210153745A (es)
CN (2) CN112545981A (es)
AU (1) AU2014318741B2 (es)
BR (1) BR112016005589B8 (es)
CA (1) CA2923426A1 (es)
IL (1) IL244356B (es)
MX (1) MX2016003394A (es)
RU (1) RU2690006C2 (es)
SA (1) SA516370737B1 (es)
WO (1) WO2015038736A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522355B (zh) * 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CA2937315A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US20210128724A1 (en) * 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815801D0 (en) * 1998-07-21 1998-09-16 Merck & Co Inc Liquid polymeric compositions for controlled released bioactive substances
EP1063992B1 (en) * 1998-03-19 2005-05-11 Merck & Co., Inc. Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations
ITRM20020357A1 (it) * 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
EP2063708A2 (en) * 2006-09-08 2009-06-03 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑

Also Published As

Publication number Publication date
BR112016005589A8 (pt) 2018-02-06
EP3046923A2 (en) 2016-07-27
NZ717327A (en) 2021-10-29
JP6612234B2 (ja) 2019-11-27
IL244356A0 (en) 2016-04-21
CA2923426A1 (en) 2015-03-19
KR20220108207A (ko) 2022-08-02
KR102337994B1 (ko) 2021-12-13
WO2015038736A3 (en) 2015-11-12
EP3915561A1 (en) 2021-12-01
US20160220552A1 (en) 2016-08-04
RU2016114537A3 (es) 2018-07-04
IL244356B (en) 2020-09-30
JP2016530316A (ja) 2016-09-29
SA516370737B1 (ar) 2021-05-27
RU2016114537A (ru) 2017-10-23
US20190070161A1 (en) 2019-03-07
BR112016005589B8 (pt) 2023-04-18
RU2690006C2 (ru) 2019-05-30
AU2014318741B2 (en) 2018-12-06
KR20210153745A (ko) 2021-12-17
CN105531275A (zh) 2016-04-27
CN112545981A (zh) 2021-03-26
KR20160055149A (ko) 2016-05-17
CN105531275B (zh) 2020-12-18
BR112016005589B1 (pt) 2022-12-06
US20210330660A1 (en) 2021-10-28
EP3046923A4 (en) 2017-03-22
WO2015038736A2 (en) 2015-03-19
AU2014318741A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
PH12016500642B1 (en) Selective substituted quinoline compounds
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
MX368455B (es) Compuestos de tetrahidropirazolopirimidina.
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12016501791B1 (en) Muscarinic receptor agonists
MX2016002571A (es) Regulador de ph de transduccion.
MX2016004629A (es) Compuestos de quinolina selectivamente sustituidos.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
EA201591748A1 (ru) Модуляторы p2x7
NZ737399A (en) Ccr2 modulators
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
NZ630908A (en) Heterocyclic compounds and methods of their use
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
IN2013MU03641A (es)
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
SA516370737B1 (ar) Cgrp صيغ لمضادات مستقبل
MX2015015051A (es) Formulaciones alternativas para polipeptidos de fusion tnfr:fc.
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201692227A1 (ru) Производные сложных аминоэфиров
JO3669B1 (ar) بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists